Nektar Therapeutics Balance Sheet - Annual (NASDAQ:NKTR)

Add to My Stocks
$22.17 $0.51 (2.35%) NKTR stock closing price Jul 20, 2017 (Closing)

A balance sheet is one of the three key financial statements released by a publicly listed company like Nektar Therapeutics, and helps in stock analysis. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our Nektar Therapeutics stock analysis. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. The Nektar Therapeutics balance sheet for 2016 shows total assets of $568.87M. Nektar Therapeutics revenue was $165.43M and Nektar Therapeutics operating cash flow was $-117.02M for the same year. View latest and last 10 year balance sheet data to check Nektar Therapeutics financial performance..

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Cash59.64M55.57M37.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M
Marketable Securities329.46M253.37M225.45M197.95M251.75M225.85M298.17M346.61M223.41M406.06M
Receivables15.67M19.94M3.6M2.22M5.8M4.93M25.1M4.8M11.16M21.63M
Inventory11.1M11.34M12.95M13.45M18.26M12.65M7.26M6.47M9.31M12.18M
Raw Materials2.05M3.23M2.2M3.94M7.48M9.75M6.1M5.93M6.96M-
Work In Progress7.31M6.08M5.18M6.14M6.66M1.21M--1.74M-
Finished Goods1.74M2.02M5.56M3.35M4.11M1.68M1.16M0.53M0.61M-
Notes Receivable----------
Other Current Assets10.36M9.81M8.81M5.17M13.36M17.94M5.67M6.18M6.74M7.1M
Nektar Therapeutics Total Current Assets
426.25M350.05M288.2M257.88M314.63M276.7M353.97M413.66M406.22M523.28M
Property Plant & Equipment176.84M174.04M164.17M151.12M144.88M140.81M143.76M132.66M117.08M-
Accumulated Depreciation111.24M102.71M93.8M84.14M72.66M62.23M53.99M54.4M43.5M-
Nektar Therapeutics Net Property Plant & Equipment
65.6M71.33M70.36M66.97M72.21M78.57M89.77M78.26M73.57M114.42M
Investment & Advances-----173.76M----
Other Non-Current Assets----------
Deferred Charges----------
Intangibles76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M81.11M
Deposits & Other Assets0.51M4.17M6.55M33.17M34.44M0.99M0.97M7.08M4.23M6.28M
Nektar Therapeutics Total Assets
568.87M502.06M441.62M434.52M497.79M606.55M521.22M575.51M560.53M725.1M
Notes Payable----------
Accounts Payable2.81M2.36M2.7M9.11M2.86M3.01M7.19M3.06M13.83M3.58M
Current Portion Long-Term Debt-----214.95M----
Current Portion Capital Leases2.9M4.75M4.51M------2.33M
Accrued Expenses35.14M22.57M26.79M44.31M41.36M31.42M29.93M28.57M39.11M70.2M
Income Taxes Payable----------
Other Current Liabilities31.35M31.55M30.04M44.78M34.31M26.12M26.97M121.37M15.42M21.96M
Nektar Therapeutics Total Current Liabilities
72.22M61.24M64.04M98.22M78.53M275.53M64.1M153.01M68.37M98.09M
Mortgages----------
Deferred Taxes/Income51.88M62.42M76.91M82.38M98.95M111.46M128.91M81.83M61.46M61.34M
Convertible Debt------214.95M214.95M214.95M315M
Long-Term Debt243.46M242.11M125M125M125M-----
Non-Current Capital Leases2.22M1.07M4.13M8.04M11.6M14.58M17.01M18.8M20.34M21.63M
Other Long-Term Liabilities110.95M128.77M135.19M210.77M136.67M7.15M5.57M4.54M5.23M14.59M
Nektar Therapeutics Total Liabilities
480.74M495.63M405.28M524.43M450.77M408.73M430.56M473.15M370.38M510.66M
Minority Interest----------
Preferred Stock----------
Common Stock Net0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Capital Surplus2.11B1.88B1.82B1.64B1.62B1.6B1.35B1.33B1.31B1.3B
Retained Earnings-2.02B-1.87B-1.79B-1.73B-1.57B-1.4B-1.26B-1.23B-1.12B-1.09B
Treasury Stock----------
Other Liabilities-2.36M-2.17M-1.56M-1.18M-0.35M-1.1M0.96M1.02M1.43M1.64M
Nektar Therapeutics Shareholders Equity
88.12M6.42M36.33M-89.9M47.01M197.81M90.66M102.36M190.15M214.43M
Nektar Therapeutics Total Liabilities & Shareholders Equity
568.87M502.06M441.62M434.52M497.79M606.55M521.22M575.51M560.53M725.1M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Balance sheet for another ticker

1:22
NKTR
Most investors just check the Nektar Therapeutics stock price, and Nektar Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Nektar Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:
  • Assets: An asset is a resource that a corporation like Nektar Therapeutics owns and has monetary significance. NKTR assets grew from $502.06M in 2015 to $568.87M in 2016 . Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Nektar Therapeutics's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for NKTR stock stand at $480.74M.
.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
4.85
Debt to Equity ratio
5.55
Asset Turnover
ratio
0.18
receivables turnover
ratio
6.64
PB ratio (
price to book ratio
)
668.2750